Seminars in Hematology
Volume 43 , Pages S1-S2 , April 2006

Inhibitor Development in Patients With Hemophilia: An Overview

  • Cindy A. Leissinger (Guest Editor)

      Affiliations

    • Corresponding Author InformationAddress correspondence to Cindy A. Leissinger, MD, Section of Hematology/Oncology, Box SL-78, Tulane University School of Medicine, 1430 Tulane Ave, New Orleans, LA 70112.

References 

  1. Evans GL , Morgan RA . Genetic induction of immune tolerance to human clotting factor VIII in a mouse model for hemophilia A . Proc Natl Acad Sci U S A . 1998;95:5734–5739
  2. Kasper CK . Diagnosis and Management of Inhibitors to Factors VIII and IX. An Introductory Discussion for Physicians . Treatment of Hemophilia Monograph Series, No. 34 . Montreal, Québec, Canada: World Federation of Hemophilia; 2004;
  3. Scharrer I , Bray GL , Neutzling O . Incidence of inhibitors in haemophilia A patients—A review of recent studies of recombinant and plasma-derived factor VIII concentrates . Haemophilia . 1999;5:145–154
  4. Key NS . Inhibitors in congenital coagulation disorders . Br J Haematol . 2004;127:379–391
  5. Young G , McDaniel M , Nugent DJ . Prophylactic recombinant factor VIIa in haemophilia patients with inhibitors . Haemophilia . 2005;11:203–207
  6. DiMichele D , Rivard G , Hay C , Antunes S . Inhibitors in haemophilia (Clinical aspects) . Haemophilia . 2004;10(suppl 4):140–145
  7. Darby SC , Keeling DM , Spooner RJ , Wan Kan S , Giangrande PL , Collins PW , et al.   The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977-99 . J Thromb Haemost . 2004;2:1047–1054
  8. DiMichele D . Immune tolerance therapy dose as an outcome predictor . Haemophilia . 2003;9:382–386
  9. DiMichele DM , Kroner BL  North American Immune Tolerance Study Group . The North American Immune Tolerance Registry (Practices, outcomes, outcome predictors) . Thromb Haemost . 2002;87:52–57
  10. DiMichele D . Inhibitors (Resolving diagnostic and therapeutic dilemmas) . Haemophilia . 2002;8:280–287
  11. Hay CR , Baglin TP , Collins PW , Hill FG , Keeling DM . The diagnosis and management of factor VIII and IX inhibitors (A guideline from the UK Haemophilia Centre Doctors’ Organization (UKHCDO)) . Br J Haematol . 2000;111:78–90
  12. Warrier I , Ewenstein BM , Koerper MA , Shapiro A , Key N , DiMichele D , et al.   Factor IX inhibitors and anaphylaxis in hemophilia B . J Pediatr Hematol Oncol . 1997;19:23–27
  13. Green D . Complications associated with the treatment of haemophiliacs with inhibitors . Haemophilia . 1999;5(suppl 3):11–17
  14. Ross-Degnan D , Soumerai SB , Avorn J , Bohn RL , Bright R , Aledort LM . Hemophilia home treatment (Economic analysis and implications for health policy) . Int J Technol Assess Health Care . 1995;11:327–344
  15. Chang H , Sher GD , Blanchette VS , Teitel JM . The impact of inhibitors on the cost of clotting factor replacement therapy in haemophilia A in Canada . Haemophilia . 1999;5:247–252

PII: S0037-1963(06)00048-5

doi: 10.1053/j.seminhematol.2006.03.002

Seminars in Hematology
Volume 43 , Pages S1-S2 , April 2006

Article Tools